azacitidine has been researched along with Local Neoplasm Recurrence in 70 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.43) | 18.7374 |
| 1990's | 3 (4.29) | 18.2507 |
| 2000's | 6 (8.57) | 29.6817 |
| 2010's | 41 (58.57) | 24.3611 |
| 2020's | 19 (27.14) | 2.80 |
| Authors | Studies |
|---|---|
| Chai, X; Chen, Y; Deng, B; Fang, Q; Huang, S; Huang, Y; Kang, Q; Li, Y; Liu, M; Ma, D; Ni, M; Wang, J; Wen, S; Zhan, Y; Zhang, F; Zhang, Y; Zhao, M; Zhao, P | 1 |
| Al-Abri, M; Chan, SM; Chow, S; Hall, V; Rashedi, I; Tang, K; Tremblay-Lemay, R; Tsui, H | 1 |
| Brasacchio, D; DiCorleto, C; Gamgee, J; Gasiorowski, R; Gregory, GP; Gruber, E; Hawkes, EA; Hogg, SJ; Jia, W; Jong, I; Kailainathan, G; Kats, LM; Kumar, B; Levy, S; Lewis, A; Luong, Q; Maher, B; Opat, S; Polekhina, G; Reynolds, J; Sabouri-Thompson, Z; Shortt, J; Skinner, H; So, J; Uhe, M; Vervoort, S; Waltham, M; Wong, J | 1 |
| Han, S; Han, Y; Li, X; Pan, T; Qi, J; Wang, H; Xu, X; Yao, Y; Zhou, M | 1 |
| Ahuja, N; Azad, NS; Baretti, M; Cope, L; Durham, JN; Heumann, TR; Leatherman, J; Linden, S; Lopez-Vidal, TY; Monga, DK; O'Dwyer, PJ; Reiss, KA; Sharma, A; Sugar, EA; Weekes, CD | 1 |
| Beach, CL; Gandhi, A; Khan, R; Lee, JK; Ma, J; Menezes, DL; Prebet, T; Risueño, A; See, WL; Skikne, B; Thakurta, A; Tsai, KT | 1 |
| Najima, Y | 1 |
| Borthakur, G; Bose, P; Daver, NG; DiNardo, CD; Duose, DY; Garcia, JS; Garcia-Manero, G; Jabbour, EJ; Jakobsen, NA; Kadia, TM; Kantarjian, H; Kim, YJ; Konopleva, M; Lachowiez, CA; Loghavi, S; Luskin, MR; Masarova, L; Ravandi, F; Short, NJ; Takahashi, K; Tanaka, T; Tidwell, RSS; Tippett, GD; Turkalj, S; Uryu, H; Vyas, P; Zeng, Z | 1 |
| Ahmadu, C; Armstrong, N; Grimm, S; Howick, J; Joore, M; McDermott, K; Noake, C; Otten, T; Witlox, W; Wolff, R | 1 |
| Byun, JM; Hong, J; Kim, D; Kim, TK; Koh, Y; Liu, J; Min, S; Park, E; Park, J; Shin, DY; Yoon, SS | 1 |
| Ciccolini, J; Correard, F; Donnette, M; Fanciullino, R; Farnault, L; Hamimed, M; Ouafik, L; Sicard, G; Venton, G | 1 |
| Bossi, P; Chen, P; Haddad, RI; Hansen, AR; Hsieh, CY; Licitra, LF; Mesia, R; Miller, J; Siu, LL; Tan, EH | 1 |
| Alvarez Secord, A; Armstrong, DK; Azab, M; Banerjee, S; Basu, B; Birrer, MJ; Blagden, SP; Braly, P; Fleming, GF; Ghamande, S; Hall, GD; Hao, Y; Hirte, HW; Jueliger, S; Keer, H; Kristeleit, R; Markham, MJ; Matei, D; Matulonis, UA; McGuire, WP; Naim, S; Nemunaitis, J; Nephew, KP; Oganesian, A; Oza, AM; Provencher, DM; Roman, LD; Schwartz, B | 1 |
| Bosi, A; Gianfaldoni, G; Grieco, P; Loscocco, GG; Palmieri, G; Piccini, M; Pilerci, S; Scappini, B | 1 |
| Bai, J; Lian, X; Pei, Z; Song, Q; Wang, H; Wang, J; Zhang, B | 1 |
| Bhagat, TD; Cheng, H; Fan, N; Gucalp, R; Halmos, B; Kim, M; Perez-Soler, R; Piperdi, B; Shah, CD; Spivack, SD; Verma, A; Zou, Y | 1 |
| Basak, GW; Biecek, P; Bołkun, Ł; Czyż, A; Drozd-Sokołowska, J; Dutka, M; Dwilewicz-Trojaczek, J; Giebel, S; Góra-Tybor, J; Gołos, A; Karakulska-Prystupiuk, E; Kobylińska, K; Kopińska, A; Mądry, K; Piekarska, A; Szwedyk, P; Waszczuk-Gajda, A | 1 |
| Bach, E; Franke, GN; Kayser, S; Kurch, L; Opitz, S; Platzbecker, U; Thomassen, K; Wang, SY | 1 |
| Chiesa, R; Mishra, AK; Mullanfiroze, K; Vora, A | 1 |
| da Costa, MJG; Ebinger, M; Frühwald, MC; Gerss, J; Hasselblatt, M; Hauser, P; Hettmer, S; Jakob, M; Johann, P; Kerl, K; Kröncke, T; Nemes, K; Reinhard, H; Schüller, U; Sehested, A; Siebert, R; Steinbügl, M; Sumerauer, D; Tüchert, S; Witt, O | 1 |
| Cui, JK; Jiang, L; Li, Q; Luo, Y; Shi, W; Xiao, Y; You, Y; Zhong, ZD | 1 |
| Chang, GS; DiPersio, JF; Duncavage, EJ; Elliott, K; Fronick, CC; Fulton, RS; Graubert, TA; Heath, SE; Jacoby, MA; Ley, TJ; Link, DC; Miller, CA; O'Laughlin, M; Pusic, I; Robinson, J; Shao, J; Walter, MJ; Welch, JS; Westervelt, P | 1 |
| Hawks, KG; Maples, KT; McCarty, JM; Sabo, RT; Toor, AA | 1 |
| Imoto, S; Konuma, T; Miyano, S; Shimizu, E; Takahashi, S; Takei, T; Tojo, A; Yamaguchi, R; Yokoyama, K | 1 |
| Fujiwara, T; Hasegawa, D; Ishida, T; Kishimoto, K; Kosaka, Y; Kozaki, A; Nakamura, S; Nino, N; Saito, A; Tahara, T; Tamura, A; Uemura, S; Yamamoto, N; Yokoi, T | 1 |
| Basak, G; Boguradzki, P; Chmarzyńska-Mróz, E; Drozd-Sokołowska, J; Dwilewicz-Trojaczek, J; Jędrzejczak, W; Karakulska-Prystupiuk, E; Kulikowska, A; Paluszewska, M; Stefaniak, A; Waszczuk-Gajda, A | 1 |
| Iijima, K; Ito, E; Mori, T; Nagano, C; Nishimura, N; Takafuji, S; Terui, K; Toki, T; Uemura, S | 1 |
| Ramos, F | 1 |
| Abbasi, T; Abbott, D; Cogle, CR; Drusbosky, L; Fullerton, A; Gutman, JA; Hammes, A; Hemenway, G; Jordan, CT; Miltgen, N; Pollyea, DA; Schatz, D; Singh, NK; Smith, C; Stevens, B; Vali, S; Wei, Q; Winters, A | 1 |
| Hale, G; Oshrine, BR; Petrovic, A; Shyr, D | 1 |
| Aziz, M; Bandyopathyay, D; Chung, H; Claiborne, J; Clark, W; Hawks, K; McCarty, J; Roberts, C; Simmons, G; Toor, A; Wiedl, C | 1 |
| Bergin, K; Bowen, KM; Couto, S; Guzman, R; Kalff, A; Khong, T; Mithraprabhu, S; Ren, Y; Reynolds, J; Spencer, A; Thakurta, A; Wang, M | 1 |
| Azab, M; Chung, W; Fung, H; Issa, JJ; Jelinek, J; Kantarjian, HM; Kelly, AD; Kropf, P; Roboz, GJ; Su, XY | 1 |
| Arai, E; Betsuyaku, T; Kanai, Y; Kohno, T; Sato, T; Soejima, K; Tsuta, K; Watanabe, S | 1 |
| Alattar, ML; Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; Dellasala, S; Faderl, S; Garcia-Manero, G; Grunwald, MR; Kadia, T; Kantarjian, H; Konopleva, M; Levis, M; Nazha, A; Pierce, S; Rajkhowa, T; Ravandi, F; Richie, MA; Rudek, MA | 1 |
| Blum, W; Byrd, JC; Devine, SM; Garzon, R; Grever, MR; Humphries, K; Klisovic, RB; Marcucci, G; Schaaf, LJ; Walker, AR | 1 |
| Ayari, S; Chevallier, P; Delaunay, J; Gastinne, T; Guillaume, T; Le Gouill, S; Loirat, M; Mohty, M; Moreau, P; Peterlin, P; Tessoulin, B | 1 |
| Akers, SN; Batt, CA; Beck, A; Gnjatic, S; Griffiths, EA; James, SR; Karpf, AR; Lele, S; Matsuzaki, J; Mhawech-Fauceglia, P; Miliotto, A; Miller, A; Odunsi, K; Ritter, G; Tsuji, T; Zhang, W | 1 |
| Inoue, A; Kawakami, C; Takitani, K; Tamai, H | 1 |
| Benmaamar, R | 1 |
| Appleton, K; Brown, R; Gabra, H; Glasspool, RM; Gore, ME; Halford, SE; Hall, GD; Kaye, S; Mackean, M; McNeish, IA; Paul, J; Pledge, S; Rustin, GJ; Ullah, R; Walker, J; Wilson, RH | 1 |
| Cha, HJ; Chang, HW; Choi, SH; Han, MW; Kim, SA; Kim, SW; Kim, SY; Lee, JC; Lee, WH; Min, YJ | 1 |
| Chen, M; Fan, H; Feng, K; Fu, X; Guo, B; Han, W; Liu, Y; Lu, X; Nie, J; Shi, F; Wang, X; Wang, Y; Zhang, W; Zhang, Y; Zhu, H | 1 |
| Bivalacqua, T; Brait, M; Driscoll, T; Hoque, MO; Maldonado, L; Michailidi, C; Munari, E; Netto, GJ; Schoenberg, M; Schultz, L; Sidransky, D | 1 |
| Chen, Y; Duan, Y; Gu, X; Hao, J; Li, L; Liu, J; Liu, Z; Shen, Z; Wang, L; Wang, Y; Zhao, W | 1 |
| Cooper, BW; Craig, MD; Creger, RJ; Hamadani, M; Kindwall-Keller, TL; Lazarus, HM; Tse, WW | 1 |
| Adomako, A; Aguirre-Ghiso, JA; Biran, N; Calvo, V; Chari, A; Moore, K; Osman, K; Paton, AW; Paton, JC; Schewe, DM | 1 |
| Carter, BZ; Dai, M; Ding, B; Jiang, L; Jiang, X; Liang, S; Liu, Q; Meng, F; Wang, Z; Ye, J; Yin, C; Yu, G; Zhang, Y; Zhao, Q; Zhong, Q | 1 |
| Benz, R; Gemuenden, C; Gerber, B; Goede, JS; Manz, MG; Senn, O | 1 |
| Benson, EA; Liu, Y; Matei, D; Nephew, KP; Skaar, TC | 1 |
| Fu, JX; Ju, SG; Li, J; Sun, Y; Wang, ZY; Yuan, YQ; Zhang, LY; Zhou, DM | 1 |
| Carter, CA; Day, RM; Lybeck, M; Oronsky, A; Oronsky, B; Oronsky, N; Richard, P; Scicinski, J; Zeman, K | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC; Wei, W | 1 |
| Basak, GW; Drozd-Sokołowska, J; Dutka, M; Dwilewicz-Trojaczek, J; Gil, L; Karakulska-Prystupiuk, E; Mądry, K; Piekarska, A; Waszczuk-Gajda, A | 1 |
| Chen, QX; Feng, XW; Wu, LM; Xie, HY; Zhang, F; Zheng, SS; Zhou, L | 1 |
| Basile, FG | 1 |
| Bertz, H; Claus, R; Finke, J; Lübbert, M; Marks, R; Rüter, B; Wäsch, R | 1 |
| Cashen, AF; DiPersio, JF; O'Donnell, MR; Schiller, GJ | 1 |
| Arnold, A; Berry, WA; Fang, F; Huang, T; Matei, D; Nephew, KP; Schilder, J; Shen, C; Zeng, Y | 1 |
| Hanaoka, N; Kurimoto, M; Matsuoka, H; Murayama, T; Nakakuma, H; Sonoki, T; Uneda, S | 1 |
| Abboud, CN; Bernabe, N; Cashen, AF; DiPersio, JF; Monahan, R; Ramsingh, G; Stockerl-Goldstein, K; Uy, GL; Vij, R; Westervelt, P | 1 |
| Mitrovic, M; Pleyer, L; Stauder, R; Steurer, M; Valentiny, C; Willenbacher, W | 1 |
| Caldas, AP; Campos, O; Cancella, AI; Dal Lago, L; DiLeone, LP; Monego, E; Pohlmann, P; Rivoire, W; Schwartsmann, G | 1 |
| Bell, SM; Carder, PJ; Hanby, AM; Horgan, K; Lane, S; Lansdown, MR; Markham, AF; Munot, K; Parkes, AT; Skliris, GP; Speirs, V | 1 |
| Baker, SD; Carducci, MA; Gilbert, J; Gore, SD; Hartke, C; He, P; Rudek, MA; Zhao, M | 1 |
| Cortes, J; Garcia-Manero, G; Gharibyan, V; Issa, JP; Jelinek, J; Kantarjian, HM; Morris, G; Talpaz, M; Verstovsek, S | 1 |
| Blessing, JA; Look, KY; Manetta, A | 1 |
| Camitta, B; Holbrook, T; Krischer, J; Land, V; Mahoney, D; Sexauer, C; Steuber, CP; Weinstein, H | 1 |
| Guastalla, JP; Renard, J; Roozendaal, KJ; Splinter, TA; Tumolo, S; Vermorken, JB | 1 |
| Gall, HE; Leyva, A; O'Brien, AM; Pinedo, HM; van Groeningen, CJ | 1 |
4 review(s) available for azacitidine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Efficacy of azacitidine in preventing relapse after hematopoietic stem cell transplantation for advanced myeloid malignancies: a systematic review and meta-analysis.
Topics: Azacitidine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local | 2022 |
Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS.
Topics: Azacitidine; Chronic Disease; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Recurrence; Transplantation, Homologous | 2023 |
Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adult; Azacitidine; Cost-Benefit Analysis; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Technology Assessment, Biomedical | 2023 |
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; CpG Islands; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histones; Humans; Hydralazine; Immunotherapy; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Nitro Compounds; Nivolumab; Prognosis; Pyridines; Treatment Outcome; Valproic Acid | 2016 |
23 trial(s) available for azacitidine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
Topics: Azacitidine; Decitabine; Genomics; Humans; Lymphoma, T-Cell, Peripheral; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neutropenia; Treatment Outcome | 2022 |
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Azacitidine; DNA Methylation; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2022 |
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
Topics: Antineoplastic Agents; Azacitidine; Humans; Isocitrate Dehydrogenase; Neoplasm Recurrence, Local | 2023 |
Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Azacitidine; Chemotherapy-Induced Febrile Neutropenia; Disease-Free Survival; Female; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Native Hawaiian or Other Pacific Islander; Neoplasm Recurrence, Local; Neutropenia; Progression-Free Survival; White People | 2019 |
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Safety; Polyethylene Glycols; Survival Rate; Topotecan; Treatment Outcome | 2020 |
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Computational Biology; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Predictive Value of Tests; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2019 |
Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study).
Topics: Adaptor Proteins, Signal Transducing; Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dexamethasone; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; Proteomics; Ubiquitin-Protein Ligases | 2019 |
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; DNA Methylation; Female; Genomics; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome; Young Adult | 2019 |
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib; Survival Rate; Tandem Repeat Sequences; Young Adult | 2013 |
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2014 |
Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cancer Vaccines; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Decitabine; DNA Methylation; Doxorubicin; Epigenesis, Genetic; Female; Gene Expression; Humans; Immunity, Humoral; Immunotherapy, Active; Long Interspersed Nucleotide Elements; Membrane Proteins; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; T-Lymphocyte Subsets; Treatment Outcome | 2014 |
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; MutL Protein Homolog 1; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Platinum | 2014 |
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Decitabine; DNA Methylation; DNA Modification Methylases; Double-Blind Method; Doxorubicin; Female; Humans; Immunotherapy; Killer Cells, Natural; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Prednisone; Prospective Studies; Survival Analysis; Vincristine | 2014 |
A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Staurosporine; Treatment Outcome | 2015 |
Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Carboplatin; Decitabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Pilot Projects; Prognosis; Survival Rate; Young Adult | 2015 |
Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2010 |
Epigenetic resensitization to platinum in ovarian cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Decitabine; Disease-Free Survival; DNA Methylation; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms | 2012 |
A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Remission Induction; Thalidomide; Young Adult | 2013 |
Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Squamous Cell; Cisplatin; Decitabine; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Uterine Cervical Neoplasms | 2002 |
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Therapy, Combination; Hematologic Neoplasms; Humans; Metabolic Clearance Rate; Neoplasm Recurrence, Local; Phenylbutyrates | 2005 |
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
A phase II study of fazarabine in patients with advanced ovarian cancer. A Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Agents; Azacitidine; Female; Humans; Infusions, Intravenous; Neoplasm Recurrence, Local; Ovarian Neoplasms; Treatment Outcome | 1995 |
Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local | 1996 |
43 other study(ies) available for azacitidine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Sulfonamides; Transplantation, Homologous; Treatment Outcome; Young Adult | 2022 |
RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Decitabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Sulfonamides; Survival Rate | 2021 |
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
Topics: Antigens, CD34; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Tumor Microenvironment | 2023 |
Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Methylation; Endogenous Retroviruses; Epigenesis, Genetic; Humans; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Rituximab | 2023 |
Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Cytidine Deaminase; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Treatment Outcome | 2023 |
Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dendritic Cells; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Sulfonamides; Treatment Outcome | 2020 |
Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Drug Combinations; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sulfonamides; Young Adult | 2020 |
First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer.
Topics: Animals; Azacitidine; Carcinoma, Non-Small-Cell Lung; DNA Methylation; Humans; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; Treatment Outcome | 2021 |
Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis.
Topics: Adolescent; Adult; Aged; Azacitidine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2021 |
Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemotherapy, Adjuvant; Dendritic Cells; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Neoplasm Recurrence, Local; Recombinant Fusion Proteins; Skin Neoplasms; Treatment Outcome | 2021 |
Azacitidine and venetoclax for post-transplant relapse in a case of CBFA2T3/GLIS2 childhood acute myeloid leukaemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Humans; Kruppel-Like Transcription Factors; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Repressor Proteins; Sulfonamides | 2021 |
Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Decitabine; Humans; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rhabdoid Tumor | 2021 |
Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Azacitidine; Child; Combined Modality Therapy; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Neoplasm Recurrence, Local; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Clonal Evolution; Clone Cells; Disease Progression; DNA Mutational Analysis; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Mutation; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2018 |
Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Case-Control Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2018 |
Azacitidine effectively reduces
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cord Blood Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Prognosis; Salvage Therapy; Tumor Suppressor Protein p53 | 2018 |
Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies | 2018 |
Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Neoplasm, Residual; Primary Myelofibrosis; Retrospective Studies; Transplantation, Homologous; Young Adult | 2018 |
Effective response to azacitidine in a child with a second relapse of myeloid leukemia associated with Down syndrome after bone marrow transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Transplantation; Child, Preschool; Down Syndrome; Female; Humans; Leukemia, Myeloid; Neoplasm Recurrence, Local | 2018 |
Pre-emptive azacitidine for relapse prevention in acute myeloid leukaemia.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Secondary Prevention | 2018 |
Low-dose azacitidine for relapse prevention after allogeneic hematopoietic cell transplantation in children with myeloid malignancies.
Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Retrospective Studies; Secondary Prevention; Tacrolimus; Transplantation, Homologous; Treatment Outcome; Young Adult | 2019 |
Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Homologous | 2019 |
DNA methylation profiles at precancerous stages associated with recurrence of lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Azacitidine; DNA Methylation; DNA Probes; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Neoplasm; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Precancerous Conditions; Proportional Hazards Models; RNA, Messenger | 2013 |
Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT.
Topics: Adolescent; Adult; Aged; Azacitidine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Transplantation, Homologous; Young Adult | 2014 |
Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Transplantation, Homologous | 2014 |
Epigenetic modification boosts ovarian cancer vaccination.
Topics: Antigens, Neoplasm; Azacitidine; Cancer Vaccines; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Treatment Outcome | 2014 |
Development of TRAIL resistance by radiation-induced hypermethylation of DR4 CpG island in recurrent laryngeal squamous cell carcinoma.
Topics: Aged; Apoptosis; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; CpG Islands; Decitabine; DNA Methylation; Dose-Response Relationship, Radiation; Epigenesis, Genetic; Female; Flow Cytometry; Gene Silencing; Humans; Immunohistochemistry; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; TNF-Related Apoptosis-Inducing Ligand | 2014 |
An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; Case-Control Studies; Cyclin A1; Cyclin D2; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Genetic Predisposition to Disease; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Predictive Value of Tests; Promoter Regions, Genetic; Urinary Bladder Neoplasms | 2014 |
[Comparative analysis of decitabine combined with DAG regimen and other regimens in treatment of refractory/relapsed acute myeloid leukemia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment.
Topics: Adult; Aged; Animals; Apoptosis; Azacitidine; Bortezomib; Cell Survival; Cyclin-Dependent Kinase 6; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Male; Mice; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; p21-Activated Kinases; Xenograft Model Antitumor Assays | 2015 |
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients.
Topics: Aclarubicin; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cytarabine; Decitabine; Disease-Free Survival; Female; Harringtonines; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Young Adult | 2015 |
Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Treatment Outcome | 2015 |
Impact of Global and Gene-Specific DNA Methylation in de Novo or Relapsed Acute Myeloid Leukemia Patients Treated with Decitabine.
Topics: Adult; Aged; Azacitidine; CpG Islands; Decitabine; Disease-Free Survival; DNA; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Octamer Transcription Factor-3; Prognosis; SOXB1 Transcription Factors; Young Adult | 2016 |
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Child; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Follow-Up Studies; Gemcitabine; Humans; Hydroxamic Acids; Lymphoma; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Vorinostat; Young Adult | 2016 |
Azacitidine Use After Allogeneic Stem Cell Transplantation-Results From the Polish Adult Leukemia Group.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Poland; Retrospective Studies; Transplantation, Homologous; Young Adult | 2016 |
Predictive value of expression and promoter hypermethylation of XAF1 in hepatitis B virus-associated hepatocellular carcinoma treated with transplantation.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Apoptosis Regulatory Proteins; Azacitidine; Carcinoma, Hepatocellular; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Hepatitis B; Hepatitis B virus; Humans; Immunoenzyme Techniques; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Rate; Tumor Cells, Cultured; Zinc Fingers | 2008 |
Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.
Topics: Acute Disease; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Decitabine; Humans; Lenalidomide; Leukemia, Myeloid; Male; Neoplasm Recurrence, Local; Remission Induction; Thalidomide | 2009 |
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Drug Administration Schedule; Epigenesis, Genetic; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2010 |
Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemtuzumab; Humans; Leukemia; Neoplasm Recurrence, Local; Tumor Cells, Cultured | 2013 |
Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia.
Topics: Aged; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Recurrence; Remission Induction; Treatment Outcome | 2013 |
Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model.
Topics: Age Factors; Azacitidine; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chi-Square Distribution; Decitabine; DNA Methylation; DNA Modification Methylases; Estrogen Receptor beta; Female; Gene Silencing; Humans; Immunohistochemistry; Lymphatic Metastasis; Neoplasm Recurrence, Local; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Uterine Cervical Dysplasia | 2003 |
5-aza-2'-deoxycytidine in advanced or recurrent cancer of the uterine cervix.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Decitabine; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 1991 |
Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.
Topics: Adult; Aged; Azacitidine; Creatine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Kinetics; Leukocyte Count; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Platelet Count; Temperature; Time Factors | 1986 |